JO Volume 5 - HIV - Clinical Care Options

Trends in the incidence of cancers among HIV-infected persons and the impact of antiretroviral therapy: a 20-year cohort study.

Authors: Crum-Cianflone N, Hullsiek KH, Marconi V, et al.

Citation: AIDS. 2009;23:41-50.

Source: Journal Options for HIV - Volume 5

Date Posted: 5/29/2009

Capsule Summary | Expert Commentary | Slideset | Abstract
A once-daily lopinavir/ritonavir-based regimen is noninferior to twice-daily dosing and results in similar safety and tolerability in antiretroviral-naive subjects through 48 weeks.

Authors: Gathe J, da Silva BA, Cohen DE, et al.

Citation: J Acquir Immune Defic Syndr. 2009;50:474-481.

Source: Journal Options for HIV - Volume 5

Date Posted: 5/29/2009

Capsule Summary | Expert Commentary | Slideset | Abstract
Race and sex differences in antiretroviral therapy use and mortality among HIV-infected persons in care.

Authors: Lemly DC, Shepherd BE, Hulgan T, et al.

Citation: J Infect Dis. 2009;199:991-998.

Source: Journal Options for HIV - Volume 5

Date Posted: 5/29/2009

Capsule Summary | Expert Commentary | Slideset | Abstract
Does less frequent routine monitoring of patients on a stable, fully suppressed cART regimen lead to an increased risk of treatment failure?

Authors: Reekie J, Mocroft A, Sambatakou H, et al.

Citation: AIDS. 2008;22:2381-2390.

Source: Journal Options for HIV - Volume 5

Date Posted: 5/29/2009

Capsule Summary | Expert Commentary | Slideset | Abstract
Incomplete reconstitution of T cell subsets on combination antiretroviral therapy in the AIDS Clinical Trials Group protocol 384.

Authors: Robbins GK, Spritzler JG, Chan ES, et al.

Citation: Clin Infect Dis. 2009;48:350-361.

Source: Journal Options for HIV - Volume 5

Date Posted: 5/29/2009

Capsule Summary | Expert Commentary | Slideset | Abstract
Effect of simultaneous use of highly active antiretroviral therapy on survival of HIV patients with tuberculosis.

Authors: Velasco M, Castilla V, Sanz J, et al.

Citation: J Acquir Immune Defic Syndr. 2009;50:148-152.

Source: Journal Options for HIV - Volume 5

Date Posted: 5/29/2009

Capsule Summary | Expert Commentary | Slideset | Abstract
Early antiretroviral therapy and mortality among HIV-infected infants.

Authors: Violari A, Cotton MF, Gibb DM, et al.

Citation: N Engl J Med. 2008;359:2233-2244.

Source: Journal Options for HIV - Volume 5

Date Posted: 5/29/2009

Capsule Summary | Expert Commentary | Slideset | Abstract
Regimen simplification to atazanavir-ritonavir alone as maintenance antiretroviral therapy: final 48-week clinical and virologic outcomes.

Authors: Wilkin TJ, McKinnon JE, DiRienzo AG, et al.

Citation: J Infect Dis. 2009;199:866-871.

Source: Journal Options for HIV - Volume 5

Date Posted: 5/29/2009

Capsule Summary | Expert Commentary | Slideset | Abstract
Detection of HIV drug resistance during antiretroviral treatment and clinical progression in a large European cohort study.

Authors: Cozzi-Lepri A, Phillips AN, Clotet B, et al.

Citation: AIDS. 2008;22:2187-2198.

Source: Journal Options for HIV - Volume 5

Date Posted: 2/24/2009

Capsule Summary | Expert Commentary | Slideset | Abstract
Maraviroc for previously treated patients with R5 HIV-1 infection.

Authors: Gulick RM, Lalezari J, Goodrich J, et al.

Citation: N Engl J Med. 2008;359:1429-1441.

Source: Journal Options for HIV - Volume 5

Date Posted: 2/24/2009

Capsule Summary | Expert Commentary | Slideset | Abstract

Jointly sponsored by Postgraduate Institute for Medicine and Clinical Care Options, LLC.

Contact Info

Educational grant provided by:

Educational grants support only the CME-certified components of this program.

Other Sites

Topics

Educational Formats

Program Resources

User Resources

PDF
Video

Help
Site Tour
RSS

Disclaimer: The materials published on the Clinical Care Options Sites reflect the views of the reviewers or authors of the CCO material, not those of Clinical Care Options, LLC, the accredited provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.

Journal Options for HIV - Volume 5 Source: Journal Options for HIV - Volume 5
Table of Contents Issue 1 Collection • Issue 1 Collection Issue 2 Collection • Issue 2 Collection Articles	Latest Content 10 of 16 Shown Trends in the incidence of cancers among HIV-infected persons and the impact of antiretroviral therapy: a 20-year cohort study. Authors: Crum-Cianflone N, Hullsiek KH, Marconi V, et al. Citation: AIDS. 2009;23:41-50. Source: Journal Options for HIV - Volume 5 Date Posted: 5/29/2009 Capsule Summary \| Expert Commentary \| Slideset \| Abstract A once-daily lopinavir/ritonavir-based regimen is noninferior to twice-daily dosing and results in similar safety and tolerability in antiretroviral-naive subjects through 48 weeks. Authors: Gathe J, da Silva BA, Cohen DE, et al. Citation: J Acquir Immune Defic Syndr. 2009;50:474-481. Source: Journal Options for HIV - Volume 5 Date Posted: 5/29/2009 Capsule Summary \| Expert Commentary \| Slideset \| Abstract Race and sex differences in antiretroviral therapy use and mortality among HIV-infected persons in care. Authors: Lemly DC, Shepherd BE, Hulgan T, et al. Citation: J Infect Dis. 2009;199:991-998. Source: Journal Options for HIV - Volume 5 Date Posted: 5/29/2009 Capsule Summary \| Expert Commentary \| Slideset \| Abstract Does less frequent routine monitoring of patients on a stable, fully suppressed cART regimen lead to an increased risk of treatment failure? Authors: Reekie J, Mocroft A, Sambatakou H, et al. Citation: AIDS. 2008;22:2381-2390. Source: Journal Options for HIV - Volume 5 Date Posted: 5/29/2009 Capsule Summary \| Expert Commentary \| Slideset \| Abstract Incomplete reconstitution of T cell subsets on combination antiretroviral therapy in the AIDS Clinical Trials Group protocol 384. Authors: Robbins GK, Spritzler JG, Chan ES, et al. Citation: Clin Infect Dis. 2009;48:350-361. Source: Journal Options for HIV - Volume 5 Date Posted: 5/29/2009 Capsule Summary \| Expert Commentary \| Slideset \| Abstract Effect of simultaneous use of highly active antiretroviral therapy on survival of HIV patients with tuberculosis. Authors: Velasco M, Castilla V, Sanz J, et al. Citation: J Acquir Immune Defic Syndr. 2009;50:148-152. Source: Journal Options for HIV - Volume 5 Date Posted: 5/29/2009 Capsule Summary \| Expert Commentary \| Slideset \| Abstract Early antiretroviral therapy and mortality among HIV-infected infants. Authors: Violari A, Cotton MF, Gibb DM, et al. Citation: N Engl J Med. 2008;359:2233-2244. Source: Journal Options for HIV - Volume 5 Date Posted: 5/29/2009 Capsule Summary \| Expert Commentary \| Slideset \| Abstract Regimen simplification to atazanavir-ritonavir alone as maintenance antiretroviral therapy: final 48-week clinical and virologic outcomes. Authors: Wilkin TJ, McKinnon JE, DiRienzo AG, et al. Citation: J Infect Dis. 2009;199:866-871. Source: Journal Options for HIV - Volume 5 Date Posted: 5/29/2009 Capsule Summary \| Expert Commentary \| Slideset \| Abstract Detection of HIV drug resistance during antiretroviral treatment and clinical progression in a large European cohort study. Authors: Cozzi-Lepri A, Phillips AN, Clotet B, et al. Citation: AIDS. 2008;22:2187-2198. Source: Journal Options for HIV - Volume 5 Date Posted: 2/24/2009 Capsule Summary \| Expert Commentary \| Slideset \| Abstract Maraviroc for previously treated patients with R5 HIV-1 infection. Authors: Gulick RM, Lalezari J, Goodrich J, et al. Citation: N Engl J Med. 2008;359:1429-1441. Source: Journal Options for HIV - Volume 5 Date Posted: 2/24/2009 Capsule Summary \| Expert Commentary \| Slideset \| Abstract 10 of 16 Shown Show 6 More Loading...	Jointly sponsored by Postgraduate Institute for Medicine and Clinical Care Options, LLC. Contact Info Educational grant provided by: Educational grants support only the CME-certified components of this program.

Source: Journal Options for HIV - Volume 5

Table of Contents

Latest Content